23:36 , Jan 17, 2018 |  BC Extra  |  Company News

Management tracks: NanoString, Orchard

Molecular diagnostics company NanoString Technologies Inc. (NASDAQ:NSTG) hired Thomas Bailey as CFO. He was CFO of AgaMatrix Holdings LLC (Salem, N.H.). Gene therapy company Orchard Therapeutics Ltd. (London, U.K.) hired Frank Thomas as CFO and...
07:00 , Jun 15, 2015 |  BioCentury  |  Emerging Company Profile

Maximizing immunogenicity

OncoQR ML is developing allogeneic cancer vaccines that use S-TIR active immunotherapy technology to increase immunogenicity compared with earlier approaches. According to co-founder, Managing Director and COO Christof Langer, the company's "warhead" approach enables a...
01:00 , Sep 28, 2013 |  BC Extra  |  Company News

Merck KGaA shuffles management team

Merck KGaA (Xetra:MRK) said Belen Garijo, currently COO of Merck Serono S.A. , Merck's biopharmaceutical division, will succeed Stefan Oschmann as president and CEO of the division, effective Oct. 1. Oschmann, who remains a director,...
08:00 , Jan 29, 2007 |  BC Week In Review  |  Company News

Allergopharma, Heska deal

Allergopharma acquired HSKA's worldwide patent portfolio and associated IP covering undisclosed allergens for an undisclosed sum. HSKA retained exclusive veterinary rights to the patent portfolio. Allergopharma Joachim-Ganzer KG , Reinbek, Germany   Heska Corp. (HSKA),...
07:00 , Aug 16, 2004 |  BC Week In Review  |  Clinical News

Birch pollen vaccine: Phase II/III data

In a double-blind, placebo-controlled European trial in 124 patients with moderate to severe rhinoconjunctivitis, an analysis of 66 patients showed that vaccination with recombinant birch pollen allergen derivatives induced a significant increase in IgG antibodies...
08:00 , Dec 13, 1999 |  BC Week In Review  |  Company News

Allergopharma Joachim Ganzer KG, Pharmacia & Upjohn Diagnostics AB deal

Allergopharma received an option to acquire co-exclusive rights to immunotherapeutic applications of P&U. s non-aliphatic forms of recombinant birch pollen allergen. Allergopharma will conduct Phase III trials with the product to treat patients allergic to...